Intervention Review

You have free access to this content

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)

  1. Lilia E Ziganshina1,*,
  2. Albina F Titarenko1,
  3. Geraint R Davies2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 6 JUN 2013

Assessed as up-to-date: 4 MAR 2013

DOI: 10.1002/14651858.CD004795.pub4


How to Cite

Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD004795. DOI: 10.1002/14651858.CD004795.pub4.

Author Information

  1. 1

    Kazan (Volga region) Federal University, Department of Basic and Clinical Pharmacology, Kazan, Tatarstan, Russian Federation

  2. 2

    University of Liverpool, Institute of Infection and Global Health, Liverpool, Merseyside, UK

*Lilia E Ziganshina, Department of Basic and Clinical Pharmacology, Kazan (Volga region) Federal University, 18 Kremlevskaya Street, 420008, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation. lezign@mail.ru. lezign@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 6 JUN 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 2 Fluoroquinolone (F-quinolone) substitution for ethambutol (E) in a standard six month regimen (HRZE), outcome: 2.2 Death from any cause (complete case analysis).
[Figure 4]
Figure 4. Forest plot of comparison: 2 Fluoroquinolone (F-quinolone) substitution for ethambutol (E) in a standard six month regimen (HRZE), outcome: 2.4 Sputum culture conversion at eight weeks (complete case analysis).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome 1 Death from any cause.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome 2 TB-related death.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome 3 Sputum culture conversion at 8 weeks.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome 4 Serious adverse events.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Fluoroquinolones plus standard regimen (HRZE) versus standard regimen alone (HRZE), Outcome 5 Total number of people with adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Fluoroquinolone substitution for ethambutol (E) in a standard six month regimen (HRZE), Outcome 1 Relapse.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Fluoroquinolone substitution for ethambutol (E) in a standard six month regimen (HRZE), Outcome 2 Death from any cause.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Fluoroquinolone substitution for ethambutol (E) in a standard six month regimen (HRZE), Outcome 3 TB-related death.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Fluoroquinolone substitution for ethambutol (E) in a standard six month regimen (HRZE), Outcome 4 Sputum culture conversion at 8 weeks.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Fluoroquinolone substitution for ethambutol (E) in a standard six month regimen (HRZE), Outcome 5 Serious adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Fluoroquinolone substitution for isoniazid (H) in a standard six month regimen (HRZE), Outcome 1 Death from any cause.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Fluoroquinolone substitution for isoniazid (H) in a standard six month regimen (HRZE), Outcome 2 TB-related death.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Fluoroquinolone substitution for isoniazid (H) in a standard six month regimen (HRZE), Outcome 3 Sputum culture conversion at 8 weeks.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Fluoroquinolone substitution for isoniazid (H) in a standard six month regimen (HRZE), Outcome 4 Serious adverse events.